Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1600RXA

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	AUG 06	CAS REGISTRY enhanced with new experimental property tags
NEWS 3	AUG 06	FSTA enhanced with new thesaurus edition
NEWS 4	AUG 13	CA/CAplus enhanced with additional kind codes for granted patents
NEWS 5	AUG 20	CA/CAplus enhanced with CAS indexing in pre-1907 records
NEWS 6	AUG 27	Full-text patent databases enhanced with predefined patent family display formats from INPADOCDB
NEWS 7	AUG 27	USPATOLD now available on STN
NEWS 8	AUG 28	CAS REGISTRY enhanced with additional experimental spectral property data
NEWS 9	SEP 07	STN AnaVist, Version 2.0, now available with Derwent World Patents Index
NEWS 10	SEP 13	FORIS renamed to SOFIS
NEWS 11	SEP 13	INPADOCDB enhanced with monthly SDI frequency
NEWS 12	SEP 17	CA/CAplus enhanced with printed CA page images from 1967-1998
NEWS 13	SEP 17	CAplus coverage extended to include traditional medicine patents
NEWS 14	SEP 24	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS 15	OCT 02	CA/CAplus enhanced with pre-1907 records from Chemisches Zentralblatt
NEWS 16	OCT 19	BEILSTEIN updated with new compounds
NEWS 17	NOV 15	Derwent Indian patent publication number format enhanced
NEWS 18	NOV 19	WPIX enhanced with XML display format
NEWS 19	NOV 30	ICSD reloaded with enhancements
NEWS 20	DEC 04	LINPADOCDB now available on STN
NEWS 21	DEC 14	BEILSTEIN pricing structure to change
NEWS 22	DEC 17	USPATOLD added to additional database clusters
NEWS 23	DEC 17	IMSDRUGCONF removed from database clusters and STN
NEWS 24	DEC 17	DGENE now includes more than 10 million sequences
NEWS 25	DEC 17	TOXCENTER enhanced with 2008 MeSH vocabulary in MEDLINE segment
NEWS 26	DEC 17	MEDLINE and LMEDLINE updated with 2008 MeSH vocabulary
NEWS 27	DEC 17	CA/CAplus enhanced with new custom IPC display formats
NEWS 28	DEC 17	STN Viewer enhanced with full-text patent content from USPATOLD
NEWS 29	JAN 02	STN pricing information for 2008 now available
NEWS 30	JAN 16	CAS patent coverage enhanced to include exemplified prophetic substances
NEWS 31	JAN 28	USPATFULL, USPAT2, and USPATOLD enhanced with new custom IPC display formats
NEWS 32	JAN 28	MARPAT searching enhanced
NEWS 33	JAN 28	USGENE now provides USPTO sequence data within 3 days of publication
NEWS 34	JAN 28	TOXCENTER enhanced with reloaded MEDLINE segment

```
 NEWS 35  JAN 28  MEDLINE and LMEDLINE reloaded with enhancements
 NEWS 36  FEB 08  STN Express, Version 8.3, now available


 NEWS EXPRESS FEBRUARY 08 CURRENT WINDOWS VERSION IS V8.3,
              AND CURRENT DISCOVER FILE IS DATED 24 JANUARY 2008

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN    Welcome Banner and News Items
 NEWS IPC8     For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 10:21:11 ON 11 FEB 2008

=> fil reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.21       0.21

FILE 'REGISTRY' ENTERED AT 10:21:23 ON 11 FEB 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   10 FEB 2008  HIGHEST RN 1002565-97-0
DICTIONARY FILE UPDATES:  10 FEB 2008  HIGHEST RN 1002565-97-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\QUERIES\105274611.str
```



chain nodes :
7 8 9 10 11
ring nodes :
1 2 3 4 5 6 12 13 14 15 16 17
chain bonds :
2-9 3-10 5-7 6-8 7-11 11-12
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 12-13 12-17 13-14 14-15 15-16 16-17
exact/norm bonds :
2-9 5-7 6-8 7-11 11-12 12-13 12-17 13-14 14-15 15-16 16-17
exact bonds :
3-10
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6

Match level :
1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:CLASS 7:CLASS 8:CLASS 9:CLASS
10:CLASS 11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS

L1 STRUCTURE UPLOADED

=> d
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

```
=> s l1
SAMPLE SEARCH INITIATED 10:21:36 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -        1 TO ITERATE

100.0% PROCESSED        1 ITERATIONS                                0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:            1 TO       80
PROJECTED ANSWERS:               0 TO        0

L2            0 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 10:21:41 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -      107 TO ITERATE

100.0% PROCESSED      107 ITERATIONS                                4 ANSWERS
SEARCH TIME: 00.00.01

L3            4 SEA SSS FUL L1

=> s l3 and caplus/lc
      56036497 CAPLUS/LC
L4            4 L3 AND CAPLUS/LC

=> fil caplus
COST IN U.S. DOLLARS                            SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                                183.51     183.72

FILE 'CAPLUS' ENTERED AT 10:21:48 ON 11 FEB 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 11 Feb 2008  VOL 148 ISS 7
FILE LAST UPDATED: 10 Feb 2008  (20080210/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l4
L5            6 L4

=> d ibib abs hitstr 1-6
```

L5 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:810510 CAPLUS
DOCUMENT NUMBER: 147:385925
TITLE: Convergent Approach for Commercial Synthesis of Gefitinib and Erlotinib
AUTHOR(S): Chandregowda, Venkateshappa; Rao, Gudapati Venkateswara; Reddy, Goukanapalli Chandrasekara
CORPORATE SOURCE: Vittal Mallya Scientific Research Foundation, Bangalore, 560004, India
SOURCE: Organic Process Research & Development (2007), 11(5), 813-816
CODEN: OPRDFK; ISSN: 1083-6160
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I



II

AB An efficient, economical and large-scale convergent synthesis of epidermal growth factor receptor tyrosine kinase inhibitors gefitinib (I, Iressa) and erlotinib (II, Tarceva), which are approved by the U.S. FDA for the treatment of non-small-cell lung cancer, is described. The formation of 4-anilinoquinazolines was achieved in a simple one-pot reaction of suitable formamidine intermediates and substituted anilines involving Dimroth rearrangement, thereby avoiding the need to make quinazolin-4(3H)-one intermediates which require large exptl. inputs. Using this process, I was prepared with overall yield of 66% from 4-methoxy-5-[3-(4-morpholinyl)propoxy]-2-nitrobenzonitrile and II in 63% yield from 4,5-bis(2-methoxyethoxy)-2-nitrobenzonitrile on a multigram scale.

IT 950596-57-3P
RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(heterocyclization of a [(morpholinopropoxy)phenyl]formamidine with chlorofluoroaniline in the large-scale com. preparation of gefitinib and erlotinib lung cancer treatment drugs)

L5 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)
RN 950596-57-3 CAPLUS
CN Methanimidamide, N'-[2-cyano-5-methoxy-4-[3-(4-morpholinyl)propoxy]phenyl]-N,N-dimethyl- (CA INDEX NAME)



IT 675126-27-9P
RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(reaction of a (morpholinopropoxy)aminobenzonitrile with DMF di-Me acetal in the large-scale com. preparation of gefitinib and erlotinib lung cancer treatment drugs)
RN 675126-27-9 CAPLUS
CN Benzonitrile, 2-amino-4-methoxy-5-[3-(4-morpholinyl)propoxy]- (CA INDEX NAME)



IT 675126-26-8
RL: RCT (Reactant); RACT (Reactant or reagent)
(reduction of a (morpholinopropoxy)nitrobenzonitrile in the large-scale com. preparation of gefitinib and erlotinib lung cancer treatment drugs)
RN 675126-26-8 CAPLUS
CN Benzonitrile, 4-methoxy-5-[3-(4-morpholinyl)propoxy]-2-nitro- (CA INDEX NAME)



L5 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:191189 CAPLUS
DOCUMENT NUMBER: 146:421938
TITLE: One-pot conversion of 2-nitrobenzonitriles to quinazolin-4(3H)-ones and synthesis of gefitinib and erlotinib hydrochloride
AUTHOR(S): Chandregowda, Venkateshappa; Rao, Gudapati Venkateswara; Reddy, Goukanapalli Chandrasekara
CORPORATE SOURCE: Vittal Mallya Scientific Research Foundation, Bangalore, 560004, India
SOURCE: Heterocycles (2007), 71(1), 39-48
CODEN: HTCYAM; ISSN: 0385-5414
PUBLISHER: Japan Institute of Heterocyclic Chemistry
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 146:421938
GI



I



II

AB A simple and efficient one-pot conversion of 2-nitrobenzonitriles to quinazolin-4(3H)-ones involving reduction, formylation, hydrolysis and cyclization is reported. E.g., quinazolin-4(3H)-one derivative I was prepared with 85% yield by reacting the corresponding 2-nitrobenzonitrile II with hydrazine using FeCl3 in MeOH/H2O followed by treating the reaction mixture with formic acid and HCl. These quinazolinones have been used for making in economical way the anticancer drug mols. gefitinib (Iressa) and erlotinib HCl (Tarceva).

IT 675126-26-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(one-pot conversion of 2-nitrobenzonitriles to quinazolin-4(3H)-ones via a nitrile reduction/formylation/hydrolysis/cyclocondensation reaction sequence with application to the synthesis of gefitinib and erlotinib hydrochloride)
RN 675126-26-8 CAPLUS
CN Benzonitrile, 4-methoxy-5-[3-(4-morpholinyl)propoxy]-2-nitro- (CA INDEX NAME)



L5 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L5 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L5 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:625376 CAPLUS
DOCUMENT NUMBER: 145:249168
TITLE: Synthesis of [11C]iressa as a new potential PET cancer
imaging agent for epidermal growth factor receptor tyrosine kinase
AUTHOR(S): Wang, Ji-Quan; Gao, Mingzhang; Miller, Kathy D.; Sledge, George W.; Zheng, Qi-Huang
CORPORATE SOURCE: Department of Radiology, Indiana University School of Medicine, Indianapolis, IN, 46202, USA
SOURCE: Bioorganic & Medicinal Chemistry Letters (2006), 16(15), 4102-4106
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 145:249168

AB Iressa (gefitinib) is an orally active inhibitor of epidermal growth factor receptor tyrosine kinase (EGFR-TK) involved in cell signal transduction processes critical to proliferation, apoptosis, repair, and angiogenesis of cancer cells. [11C]Iressa was first designed and synthesized as a new potential positron emission tomog. (PET) cancer imaging agent for EGFR-TK in 30-40% radiochem. yield with 4.0-6.0 Ci/μmol specific activity at end of bombardment (EOB).

IT 675126-26-8P 675126-27-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of carbon-11 iressa as PET cancer imaging agent for epidermal
growth factor receptor tyrosine kinase)

RN 675126-26-8 CAPLUS
CN Benzonitrile, 4-methoxy-5-[3-(4-morpholinyl)propoxy]-2-nitro- (CA INDEX NAME)



RN 675126-27-9 CAPLUS
CN Benzonitrile, 2-amino-4-methoxy-5-[3-(4-morpholinyl)propoxy]- (CA INDEX NAME)



L5 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:696894 CAPLUS
DOCUMENT NUMBER: 143:194029
TITLE: An improved process for preparation of gefitinib, useful as antitumor agent
INVENTOR(S): Jyothi Prasad, Ramanadham; Pulla Reddy, Muddasani; Nageshwara Rao, Bollepalli; Venkaiah Chowdary, Nannapaneni
PATENT ASSIGNEE(S): Natco Pharma Limited, India
SOURCE: PCT Int. Appl., 53 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005070909	A1	20050804	WO 2004-IN223	20040727
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
IN 2004CH00046	A	20060526	IN 2004-CH46	20040122
PRIORITY APPLN. INFO.:			IN 2004-CH46 A	20040122

OTHER SOURCE(S): CASREACT 143:194029
GI

L5 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



I



II

AB The invention relates to an improved preparation of gefitinib (I), useful as
antitumor agent (no biol. data). For instance, gefitinib was prepared via
heterocyclization of aminobenzamide derivative II with formic acid, chlorination of the obtained 3,4-dihydroquinazoline-4-one derivative, and amination of the obtained 4-chloroquinazoline derivative by 3-chloro-4-fluoroaniline.

IT 675126-26-8P
RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(improved process for preparation of gefitinib useful as antitumor agent)

RN 675126-26-8 CAPLUS
CN Benzonitrile, 4-methoxy-5-[3-(4-morpholinyl)propoxy]-2-nitro- (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:238968 CAPLUS
DOCUMENT NUMBER: 142:298128
TITLE: A process of manufacturing gefitinib via rearrangement of iminoquinazoline derivative
INVENTOR(S): Gilday, John Peter; Welham, Matthew James
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited
SOURCE: PCT Int. Appl., 29 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005023783	A1	20050317	WO 2004-GB3720	20040901

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: GB 2003-20793 A 20030905

OTHER SOURCE(S): CASREACT 142:298128
GI

L5 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



I



II

AB The invention relates to an improved process for manufacture of gefitinib (I)
via rearrangement reaction of quinazoline derivative II. Gefitinib was prepared
via heterocyclization of N,N'-bis-(3-chloro-4-fluorophenyl)formamidine and
2-amino-4-methoxy-5-(3-morpholinopropoxy)benzonitrile and subsequent rearrangement of the obtained iminoquinazoline derivative II.

IT 675126-26-8P 675126-27-9P 847862-72-0P
RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(process of manufacturing gefitinib useful as EGFR inhibitor)

RN 675126-26-8 CAPLUS
CN Benzonitrile, 4-methoxy-5-[3-(4-morpholinyl)propoxy]-2-nitro- (CA INDEX NAME)



RN 675126-27-9 CAPLUS
CN Benzonitrile, 2-amino-4-methoxy-5-[3-(4-morpholinyl)propoxy]- (CA INDEX NAME)

L5 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)



RN 847862-72-0 CAPLUS
CN Methanimidamide, N-(3-chloro-4-fluorophenyl)-N'-[2-cyano-5-methoxy-4-[3-(4-morpholinyl)propoxy]phenyl]- (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:252492 CAPLUS
DOCUMENT NUMBER: 140:287403
TITLE: Preparation of 4-(3'-chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline
INVENTOR(S): Gilday, John Peter; Moody, David
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca Uk Limited
SOURCE: PCT Int. Appl., 32 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004024703	A1	20040325	WO 2003-GB3923	20030909
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2498122	A1	20040325	CA 2003-2498122	20030909
AU 2003263348	A1	20040430	AU 2003-263348	20030909
AU 2003263348	B2	20071011		
EP 1546119	A1	20050629	EP 2003-795077	20030909
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003014238	A	20050726	BR 2003-14238	20030909
CN 1681796	A	20051012	CN 2003-821550	20030909
JP 2006508922	T	20060316	JP 2004-535657	20030909
NZ 538552	A	20070223	NZ 2003-538552	20030909
NO 2005001104	A	20050601	NO 2005-1104	20050301
ZA 2005001892	A	20050908	ZA 2005-1892	20050304
MX 2005PA02601	A	20050505	MX 2005-PA2601	20050308
US 2006003999	A1	20060105	US 2005-527461	20050311
IN 2007DN07004	A	20070928	IN 2007-DN7004	20070910

PRIORITY APPLN. INFO.:
GB 2002-21245 A 20020913
WO 2003-GB3923 W 20030909
IN 2005-DN871 A3 20050304

OTHER SOURCE(S): CASREACT 140:287403; MARPAT 140:287403
GI



III

L5 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)

AB The invention relates to chemical processes and intermediates useful in the manufacture of the title quinazoline (I). Thus, reacting 4-methoxy-5-(3-morpholinopropoxy)-2-nitrobenzonitrile with sodium dithionite in water gave 2-amino-4-methoxy-5-(3-morpholinopropoxy)benzonitrile (II). II was then converted to the benzamide; the benzamide was condensed with formamide to give quinazolinone III. III was treated with phosphorus oxychloride to give 4-chloro-7-methoxy-6-(3-morpholinopropoxy)quinazoline which alkylated 3-chloro-4-fluoroaniline to give I. The synthesis of II is also represented.

IT 675126-26-8P, 4-Methoxy-5-(3-morpholinopropoxy)-2-nitrobenzonitrile 675126-27-9P, 2-Amino-4-methoxy-5-(3-morpholinopropoxy)benzonitrile
RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of 4-(3'-chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline)

RN 675126-26-8 CAPLUS
CN Benzonitrile, 4-methoxy-5-[3-(4-morpholinyl)propoxy]-2-nitro- (CA INDEX NAME)



RN 675126-27-9 CAPLUS
CN Benzonitrile, 2-amino-4-methoxy-5-[3-(4-morpholinyl)propoxy]- (CA INDEX NAME)



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> log y
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                      ENTRY    SESSION
FULL ESTIMATED COST                                    33.66     217.38

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                      ENTRY    SESSION
CA SUBSCRIBER PRICE                                    -4.80      -4.80

STN INTERNATIONAL LOGOFF AT 10:22:53 ON 11 FEB 2008
```